X
Indications

ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be taken with methotrexate or used alone. Read More

ENBREL is indicated for chronic moderate to severe plaque psoriasis (PsO) in children 4 years and older and adults who may benefit from taking injections or pills (systemic therapy) or phototherapy (ultraviolet light). 
ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with psoriatic arthritis. ENBREL can be used with or without methotrexate.
ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis. 
ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in children ages 2 years and older. Close
Download Statwise to track your progress

See signs of improvement you may be
missing with STATWISE™

Download Statwise to track your progress

See signs of improvement you may be missing with STATWISE™

It’s natural to feel both hopeful and anxious when you start a new treatment.

To help answer the question, “Is ENBREL working for me?” we’ve developed STATWISE™—a simple-to-use text message program that helps you track your symptoms. So you may better understand the changes you might be experiencing over time.

For 12 weeks, you’ll be sent 3 text messages every day about your symptoms including pain, fatigue, morning stiffness, and if you have psoriatic arthritis, arthritis activity. Simply take a few seconds in the morning, afternoon, and evening to respond back and rate your symptoms (for example: “0” for no pain, “10” for extreme pain). By responding to the STATWISE™ messages throughout the day, you may get an accurate understanding of your progress and notice patterns in your symptoms.

STATWISE™ keeps track of your responses and sends you a symptom report every 2 weeks capturing the changes you’ve experienced. Then, you can easily share your results with your doctor or loved ones.

Enroll in STATWISE™ today

Before we start, are you currently enrolled in ENBREL Support®?

Please provide the information that you used to enroll in ENBREL Support®

Date of birth

Full date of birth is required

Select your condition:

STATWISE™ is only available for patients with Moderate to Severe Rheumatoid Arthritis or Psoriatic Arthritis.

You must complete all required information above to proceed.

Get STATWISE™

We found your information! Just 2 more quick questions.

Is your mobile phone a smartphone? (eg, iPhone or Android phone)

Day of the week you will take your prescribed ENBREL injection

Day of the week is required
You must complete all required information above to proceed.

Success! What’s Next?

You will receive a welcome text message on your mobile phone and 4 additional text messages that will provide you with important program terms. After you have read those messages carefully, reply START to the last message to accept the terms and confirm your enrollment in the STATWISE™ program. You will receive a text message confirming your enrollment. Then you will start receiving the STATWISE™ program text messages the next day.

For detailed instructions, go to the Instructions & FAQs page.

We’re sorry, but the information you entered does not match our records. Please try again, or contact the ENBREL Support® team at 1-888-4ENBREL.

We’re sorry, but an error has occurred.
Please try again, or contact the ENBREL Support® team at 1-888-4ENBREL.

+ See More

Important Safety Information

What is the most important information I should know about ENBREL?

ENBREL is a medicine that affects your immune

ENBREL is a medicine that affects your immune system. ENBREL can lower the ability of your immune system to fight infections. Serious infections
have happened in patients taking ENBREL. These infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have

 
Close
Prescription Enbrel® (etanercept) is taken (given) by injection.

Important Safety Information

What is the most important information I should know about ENBREL?

ENBREL is a medicine that affects your immune system. ENBREL can lower the ability of your immune system to fight infections. Serious infections have happened in patients taking ENBREL. These infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some patients have died from these infections. Your healthcare provider should test you for TB before you take ENBREL and monitor you closely for TB before, during, and after ENBREL treatment, even if you have tested negative for TB.

There have been some cases of unusual cancers, some resulting in death, reported in children and teenage patients who started using tumor necrosis factor (TNF) blockers before 18 years of age. Also, for children, teenagers, and adults taking TNF blockers, including ENBREL, the chances of getting lymphoma or other cancers may increase. Patients with RA may be more likely to get lymphoma.

Before starting ENBREL, tell your healthcare provider if you:

  • Have any existing medical conditions
  • Are taking any medicines, including herbals
  • Think you have, are being treated for, have signs of, or are prone to infection. You should not start taking ENBREL if you have any kind of infection, unless your healthcare provider says it is okay
  • Have any open cuts or sores
  • Have diabetes, HIV, or a weak immune system
  • Have TB or have been in close contact with someone who has had TB
  • Were born in, lived in, or traveled to countries where there is more risk for getting TB. Ask your healthcare provider if you are not sure
  • Live, have lived in, or traveled to certain parts of the country (such as, the Ohio and Mississippi River valleys, or the Southwest) where there is a greater risk for certain kinds of fungal infections, such as histoplasmosis. These infections may develop or become more severe if you take ENBREL. If you don’t know if these infections are common in the areas you’ve been to, ask your healthcare provider
  • Have or have had hepatitis B
  • Have or have had heart failure
  • Develop symptoms such as persistent fever, bruising, bleeding, or paleness while taking ENBREL
  • Use the medicine Kineret (anakinra), Orencia (abatacept), or Cytoxan (cyclophosphamide)
  • Are taking anti-diabetic medicines
  • Have, have had, or develop a serious nervous disorder, seizures, any numbness or tingling, or a disease that affects your nervous system such as multiple sclerosis or Guillain-Barré syndrome
  • Are scheduled to have surgery
  • Have recently received or are scheduled for any vaccines. All vaccines should be brought up-to-date before starting ENBREL. Patients taking ENBREL should not receive live vaccines.
  • Are allergic to rubber or latex
  • Are pregnant, planning to become pregnant, or breastfeeding
  • Have been around someone with chicken pox

What are the possible side effects of ENBREL?

ENBREL can cause serious side effects including: New infections or worsening of infections you already have; hepatitis B can become active if you already have had it; nervous system problems, such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes; blood problems (some fatal); new or worsening heart failure; new or worsening psoriasis; allergic reactions; autoimmune reactions, including a lupus-like syndrome and autoimmune hepatitis.

Common side effects include: Injection site reactions and upper respiratory infections (sinus infections).

In general, side effects in children were similar in frequency and type as those seen in adult patients. The types of infections reported were generally mild and similar to those usually seen in children.

These are not all the side effects with ENBREL. Tell your healthcare provider about any side effect that bothers you or does not go away.

If you have any questions about this information, be sure to discuss them with your healthcare provider. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see Prescribing Information and Medication Guide.

Indications

Moderate to Severe Rheumatoid Arthritis (RA)

ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be taken with methotrexate or used alone.

Psoriatic Arthritis

ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with psoriatic arthritis. ENBREL can be used with or without methotrexate.

Moderate to Severe Plaque Psoriasis

ENBREL is indicated for chronic moderate to severe plaque psoriasis (PsO) in children 4 years and older and adults who may benefit from taking injections or pills (systemic therapy) or phototherapy (ultraviolet light).

Ankylosing Spondylitis (AS)

ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

Moderately to Severely Active Polyarticular Juvenile Idiopathic Arthritis (JIA)

ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in children ages 2 years and older.

The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Amgen is under license.

References: 1. Parsabiv® (etelcalcetide) prescribing information, Amgen. 2. Data on file, Amgen; [Summary of Clinical Efficacy; 2015]. 3. Alexander ST, et al. Mol Pharmacol. 2015;88:853-865. 4. Data on file, Amgen; [Report R20130052, 2014]. 5. Chen P, et al. CPT Pharmacometrics Syst Pharmacol. 2016;5:484-494. 6. Sensipar® (cinacalcet) prescribing information, Amgen. 7. Ma JN, et al. J Pharmacol Exp Ther. 2011;337:275-284.
X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.